AbbVie Inc. [NYSE: ABBV] price surged by 0.81 percent to reach at $1.12. The company report on September 7, 2022 that Allergan Aesthetics Celebrates 100 Million Syringes of JUVÉDERM®.
Top 5 Cheap Stocks to Own Right Now
While finding safe stocks with the potential for monster gains isn't always easy, we've found a few that could pay out well. In fact, within our report, "Top 5 Cheap Stock to Own Right Now", we have identified five stocks we believe could appreciate the most even if you just have $1,000 to invest.
Sign up here to get your free report now.
JUVÉDERM® Collection of Fillers Continues Position as the World’s Number One Chosen Dermal Filler Collection.
Today, Allergan Aesthetics, an AbbVie company (NYSE: ABBV), announced its manufacturing facility in France has reached the milestone of producing and shipping 100 million syringes of JUVÉDERM® products globally. 1 Since its launch in 2000, the JUVÉDERM® Collection of Fillers has grown to where its products are now available in more than 110 territories worldwide and it remains the world’s number one chosen dermal filler collection. 2,3 This remarkable achievement is a milestone years in the making, and further demonstrates the JUVÉDERM® Collection of Fillers’ dedication to patients and providers globally.
A sum of 4135081 shares traded at recent session while its average daily volume was at 5.57M shares. AbbVie Inc. shares reached a high of $139.04 and dropped to a low of $135.34 until finishing in the latest session at $138.71.
The one-year ABBV stock forecast points to a potential upside of 12.29. The average equity rating for ABBV stock is currently 2.20, trading closer to a bullish pattern in the stock market.
Guru’s Opinion on AbbVie Inc. [ABBV]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for ABBV shares is $158.14 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on ABBV stock is a recommendation set at 2.20. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
Atlantic Equities have made an estimate for AbbVie Inc. shares, keeping their opinion on the stock as Neutral, with their previous recommendation back on August 01, 2022. While these analysts kept the previous recommendation, SVB Leerink raised their target price to Underperform. The new note on the price target was released on May 23, 2022, representing the official price target for AbbVie Inc. stock. Previously, the target price had yet another raise to $150, while Daiwa Securities analysts kept a Neutral rating on ABBV stock.
The Average True Range (ATR) for AbbVie Inc. is set at 2.88, with the Price to Sales ratio for ABBV stock in the period of the last 12 months amounting to 4.34. The Price to Book ratio for the last quarter was 16.75, with the Price to Cash per share for the same quarter was set at 5.55. Price to Free Cash Flow for ABBV in the course of the last twelve months was 19.85 with Quick ratio for the last quarter at 0.70.
ABBV Stock Performance Analysis:
AbbVie Inc. [ABBV] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 2.33. With this latest performance, ABBV shares dropped by -1.16% in over the last four-week period, additionally sinking by -5.74% over the last 6 months – not to mention a rise of 27.22% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for ABBV stock in for the last two-week period is set at 46.22, with the RSI for the last a single of trading hit 50.34, and the three-weeks RSI is set at 44.57 for AbbVie Inc. [ABBV]. The present Moving Average for the last 50 days of trading for this stock 144.79, while it was recorded at 137.10 for the last single week of trading, and 144.45 for the last 200 days.
Insight into AbbVie Inc. Fundamentals:
Operating Margin for any stock indicates how profitable investing would be, and AbbVie Inc. [ABBV] shares currently have an operating margin of +35.14 and a Gross Margin at +69.49. AbbVie Inc.’s Net Margin is presently recorded at +20.41.
Return on Equity for this stock inclined to 80.52, with Return on Assets sitting at 7.72.
AbbVie Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 0.70 and a Current Ratio set at 0.80.
ABBV Stock EPS
The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for ABBV. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for AbbVie Inc. go to -0.57%.
AbbVie Inc. [ABBV] Insider Position Details
There are presently around $169,977 million, or 72.20% of ABBV stock, in the hands of institutional investors. The top three institutional holders of ABBV stocks are: VANGUARD GROUP INC with ownership of 153,579,751, which is approximately 2.034% of the company’s market cap and around 0.11% of the total institutional ownership; BLACKROCK INC., holding 134,700,648 shares of the stock with an approximate value of $18.68 billion in ABBV stocks shares; and STATE STREET CORP, currently with $10.7 billion in ABBV stock with ownership of nearly -1.177% of the company’s market capitalization.
Positions in AbbVie Inc. stocks held by institutional investors increased at the end of July and at the time of the July reporting period, where 1,288 institutional holders increased their position in AbbVie Inc. [NYSE:ABBV] by around 73,492,701 shares. Additionally, 1,480 investors decreased positions by around 52,767,961 shares, while 400 investors held positions by with 1,099,151,026 shares. The mentioned changes placed institutional holdings at 1,225,411,688 shares, according to the latest SEC report filing. ABBV stock had 131 new institutional investments in for a total of 3,481,543 shares, while 138 institutional investors sold positions of 5,507,450 shares during the same period.